Welcome to our dedicated page for Denali Therapeut SEC filings (Ticker: DNLI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Denali Therapeutics Inc. (DNLI) SEC filings page on Stock Titan provides access to the company’s publicly filed documents, including current reports on Form 8‑K and other disclosures incorporated by reference. Denali is a biotechnology and biopharmaceutical company based in South San Francisco, California, focused on product candidates engineered to cross the blood-brain barrier for neurodegenerative and lysosomal storage diseases.
Recent Form 8‑K filings referenced by the company include reports of quarterly financial results, such as second and third quarter 2025 results, and Regulation FD disclosures related to key regulatory milestones. For example, Denali filed 8‑K reports describing FDA acceptance and Priority Review of the Biologics License Application for tividenofusp alfa (DNL310) for Hunter syndrome (MPS II), and a subsequent extension of the Prescription Drug User Fee Act (PDUFA) target action date after submission of updated clinical pharmacology information classified as a Major Amendment.
Through this page, users can track how Denali reports material events such as clinical and regulatory updates, financial results and capital markets transactions, including public offerings of common stock and pre-funded warrants registered on Form S‑3. The filings complement the company’s press releases by providing formal regulatory context and references to exhibits such as earnings releases and detailed financial statements.
Stock Titan enhances access to these filings with tools designed to help readers quickly locate relevant 8‑K disclosures, review historical reporting patterns and connect SEC documents with related news about Denali’s TransportVehicle™ platform, pipeline programs and collaborations.
Denali Therapeutics insider Carole Ho has filed a Rule 144 notice to sell 39,490 shares of common stock. The shares are to be sold on NASDAQ through Morgan Stanley Smith Barney LLC Executive Financial Services, with an indicated aggregate market value of
The shares were acquired on
A person named Carole Ho has filed a Rule 144 notice indicating an intention to sell 150,000 shares of common stock through Morgan Stanley Smith Barney LLC on NASDAQ. The filing lists an aggregate market value of
The notice also reports that on
A shareholder in DNLI has filed a notice of intent to sell 150,000 shares of common stock on the NASDAQ, with an aggregate market value of $3,324,060. The planned sales are to be executed through Morgan Stanley Smith Barney LLC Executive Financial Services, with an approximate sale date of February 3, 2026.
The shares were acquired on February 2, 2026 by exercising stock options under a registered plan, in three transactions for 22,042, 44,021, and 83,937 shares, all paid in cash. The filing notes that there were 146,661,833 shares of this class of stock outstanding.
Denali Therapeutics Inc. President and CEO Ryan J. Watts reported a sale of common stock in a Form 4 filing. On January 6, 2026, he sold 35,198 shares of Denali common stock at $16.50 per share, and the filing explains that these shares were sold to satisfy tax obligations related to the settlement of previously vested restricted stock units (RSUs). Following this transaction, he directly beneficially owned 296,833 shares, which include 184,915 unvested RSUs. The filing also reports an additional 2,152,604 shares held indirectly through the Watts Family 2015 Trust, for which he serves as trustee.
Denali Therapeutics Inc. officer Alexander O. Schuth, the company’s COFO and Secretary, reported a sale of common stock. On 01/06/2026, he sold 17,218 shares of Denali common stock at $16.5 per share, with the filing stating that the sale was made to satisfy his tax obligations related to the settlement of previously vested restricted stock units (RSUs). After this transaction, he beneficially owned 282,828 shares directly, which the filing notes includes 141,100 unvested RSUs. The filing also reports 523,749 shares held indirectly through The Schuth Family Trust U/A DTD 06/05/2017, for which he serves as trustee.
A shareholder of Denali Therapeutics Inc. has filed a notice of proposed sale under Rule 144 covering 35,198 shares of common stock. The shares are to be sold through Morgan Stanley Smith Barney LLC Executive Financial Services on or about 01/06/2026 on the NASDAQ, with an aggregate market value listed as
Denali Therapeutics Inc. filed a current report to share that it has issued a press release outlining an update on its programs and expected milestones for 2026, and its planned participation in the 44th Annual J.P. Morgan Healthcare Conference. The press release is provided as Exhibit 99.1 and is incorporated by reference. The company notes that the information under Regulation FD in this report, including Exhibit 99.1, is being furnished rather than filed, which limits how it is treated under securities law.
Denali Therapeutics Inc. insiders affiliated with Baker Brothers reported large purchases of $0.01 prefunded warrants to buy the company’s common stock. On December 11, 2025, 667, L.P. acquired 190,523 prefunded warrants and Baker Brothers Life Sciences, L.P. acquired 2,095,191 prefunded warrants in a public offering at $17.49 per warrant. Each warrant is exercisable at any time on a 1-for-1 basis into common stock at an exercise price of $0.01 per share, with no expiration date.
These warrants can only be exercised to the extent the holders and their affiliates would beneficially own no more than 4.99% of Denali’s outstanding common stock, a cap that can be adjusted up to 19.99% with 61 days’ notice. After these transactions, 667, L.P. beneficially owned 2,335,469 prefunded warrants and Baker Brothers Life Sciences, L.P. beneficially owned 25,996,310 prefunded warrants. Julian C. Baker is a director of Denali, and other reporting persons are deemed directors by deputization through their board representation and advisory roles.
Denali Therapeutics (DNLI) filed a Form 4 for a director equity grant. On 11/04/2025, the director received 10,632 restricted stock units at $0 and was shown beneficially owning 10,632 common shares after the transaction, held directly.
The director was also granted a stock option for 31,897 shares at an exercise price of $14.92, expiring 11/04/2034. RSUs vest in four equal annual installments from the grant date, subject to service. Options vest 25% on November 4, 2026, with the remainder vesting monthly in equal 1/48 increments thereafter.
Denali Therapeutics (DNLI) reported an insider Form 3 for a board member. The filing identifies the reporting person as a Director and indicates it is filed by one reporting person. The event date is 11/04/2025. In the remarks, the filer states no securities are beneficially owned. The signature block shows execution on 11/06/2025 by attorney-in-fact.